X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to accelerate new drug discovery in cancer treatment combining Ichnos' research and development proficiencies in novel biologics with those of Glenmark in new small molecules, including GRC 54276, to treat hematological malignancies and solid tumors.
Lead Product(s): GRC 54276,Pembrolizumab
Therapeutic Area: Oncology Product Name: GRC 54276
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Glenmark Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 30, 2024
Details:
Under the terms of the license agreement, Astria plans to develop the lead candidate, called STAR-0310, a monoclonal antibody OX40 antagonist that incorporates YTE half-life extension technology, for the treatment of AD.
Lead Product(s): STAR-0310
Therapeutic Area: Dermatology Product Name: STAR-0310
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Astria Therapeutics
Deal Size: $320.0 million Upfront Cash: $15.0 million
Deal Type: Licensing Agreement October 11, 2023
Details:
ISB 2001, Ichnos' third clinical-stage asset to receive ODD for the treatment of multiple myeloma, is the company's first BCMA x CD38 x CD3 TREAT™ trispecific antibody based on the company's proprietary BEAT® platform, which enables the development of immune cell engagers.
Lead Product(s): ISB 2001
Therapeutic Area: Oncology Product Name: ISB 2001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2023
Details:
ISB 1442 is a biparatopic 2+1 BEAT® bispecific antibody targeting CD38 and CD47, for the treatment of acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL).
Lead Product(s): ISB 1442
Therapeutic Area: Oncology Product Name: ISB 1442
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
ISB 1442 is a biparatopic bispecific antibody that combines two proprietary anti-CD38 binding arms, each targeting different regions on CD38, with an antagonistic anti-CD47 arm, making it equivalent to a trispecific antibody.
Lead Product(s): ISB 1442
Therapeutic Area: Oncology Product Name: ISB 1442
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
In vitro studies showed that ISB 2001 exhibited increased killing potency of tumor cells compared to all tested antibodies that are either currently approved therapeutics for multiple myeloma or being tested in ongoing clinical studies.
Lead Product(s): ISB 2001
Therapeutic Area: Oncology Product Name: ISB 2001
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
Under the agreement, Almirall is granted global rights to develop and commercialize ISB 880, monoclonal antibody for autoimmune diseases. Ichnos will retain rights for antibodies acting on the IL-1RAP pathway for oncology indications.
Lead Product(s): ISB 880
Therapeutic Area: Immunology Product Name: ISB 880
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Almirall
Deal Size: Undisclosed Upfront Cash: $23.6 million
Deal Type: Licensing Agreement December 14, 2021
Details:
The two highest doses of telazorlimab, 300 mg and 600 mg administered every two weeks, were statistically superior to placebo. Telazorlimab was well-tolerated during the study to date.
Lead Product(s): Telazorlimab
Therapeutic Area: Dermatology Product Name: ISB 830
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Glenmark Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
